论文部分内容阅读
采用药物利用评价法(DUR)和药物利用评估法(DUE)相结合,对冠心病120例患者的临床用药情况进行评价与分析。主要治疗用药29种,7种药物DUI<1,18种药物DUI=1,4种药物DUI>1。使用频度占前3位的药物分别为阿司匹林肠溶片、缬沙坦胶囊、硫酸氢氯吡格雷片。在DUE评价中,对于用药前心电图、肝肾功能等检查率为100%,但是对于用药后异常指标再监测,各指标各异。以DUI和DUE为评价程序,可以从药物的治疗前、治疗过程监测和治疗效果评价等来综合评价用药合理性。
Drug use evaluation (DUR) and drug utilization evaluation (DUE) were combined to evaluate the clinical use of 120 patients with coronary heart disease. The main treatment medication 29 kinds, seven kinds of drugs DUI <1,18 kinds of drugs DUI = 1,4 kinds of drugs DUI> 1. Frequency of use of the top three drugs were aspirin enteric-coated tablets, valsartan capsules, clopidogrel hydrogen sulfate tablets. In the DUE evaluation, for the pre-medication ECG, liver and kidney function check rate of 100%, but for the abnormal indicators after drug monitoring, the indicators vary. With DUI and DUE as the evaluation procedure, the rationality of medication can be comprehensively evaluated from the pre-treatment of drugs, the monitoring of treatment process and the evaluation of therapeutic effects.